hydroxychloroquine has been researched along with bortezomib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amaravadi, RK; Bradner, JE; Chang, YC; Davis, LE; Heitjan, DF; Kaplan, J; Mallon, G; Nichols, CW; Paul, TM; Piao, S; Pontiggia, L; Porter, DL; Rangwala, R; Scott, EC; Stadtmauer, EA; Tan, KS; Vogl, DT | 1 |
| Amaravadi, RK; Boyiadzis, M; Johnson, DE; Konig, H; Lotze, MT; Sehgal, AR; Tang, D | 1 |
| Hudes, GR; Kruger, WD; Lee, HO; Mustafa, A | 1 |
| Baranowska, K; Bjørkøy, G; Buene, G; Darvekar, S; Holien, T; Johansson, I; Misund, K; Starheim, KK; Sundan, A; Waage, A | 1 |
| Deng, J; Li, ZY; Liu, HM; Shi, MY; Yao, Y; Yuan, CL | 1 |
| Abraham, NG; Alcalai, R; Arad, M; Hochhauser, E; Petrover, Z; Seidman, CE; Seidman, J; Shainberg, A; Waldman, M; Yadin, D | 1 |
2 review(s) available for hydroxychloroquine and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
Topics: Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; HMGB1 Protein; Humans; Hydroxychloroquine; Leukemia; Leukocytes; Lysosomes; Phagosomes; Pyrazines; Sirolimus | 2015 |
1 trial(s) available for hydroxychloroquine and bortezomib
| Article | Year |
|---|---|
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2014 |
5 other study(ies) available for hydroxychloroquine and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Hydroxychloroquine Destabilizes Phospho-S6 in Human Renal Carcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Everolimus; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hydroxychloroquine; Kidney; Mitochondria; Oxygen Consumption; Proteasome Endopeptidase Complex; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxychloroquine; Lysosomes; Macrolides; Microscopy, Confocal; Microscopy, Fluorescence; Multiple Myeloma; Oligopeptides; Primary Cell Culture; Proteasome Endopeptidase Complex; Proteolysis; Sequestosome-1 Protein | 2016 |
[The Inhibiting Effect of Autophagy Inhibitor ROC-325 on Multiple Myeloma].
Topics: Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Hydroxychloroquine; Multiple Myeloma | 2021 |
Autophagy guided interventions to modify the cardiac phenotype of Danon disease.
Topics: Animals; Autophagy; Bortezomib; Cardiomegaly; Cardiomyopathies; Glycogen Storage Disease Type IIb; Humans; Hydroxychloroquine; Mice; Phenotype; Proteasome Endopeptidase Complex; Sirolimus | 2022 |